Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:INONYSE:MLSSNASDAQ:PTHLNASDAQ:ZYXI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeINOInovio Pharmaceuticals$2.17+2.1%$1.83$1.42▼$12.33$79.40M1.4603,593 shs333,923 shsMLSSMilestone Scientific$0.91-1.0%$0.95$0.58▼$1.39$71.49M0.93127,876 shs5,656 shsPTHLPheton Holdings Ltd Class A Ordinary Shares$6.13+1.7%$4.15$1.32▼$7.31$40.32MN/A185,457 shs1.37 million shsZYXIZynex$2.19+2.3%$2.24$1.66▼$10.62$66.22M0.7165,339 shs46,699 shs20 Stocks to Sell NowToday, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceINOInovio Pharmaceuticals+0.95%+6.00%+10.42%+7.61%-79.13%MLSSMilestone Scientific-2.65%-5.45%-15.60%-9.80%+19.95%PTHLPheton Holdings Ltd Class A Ordinary Shares-4.29%+5.61%+47.91%+137.48%+601,999,900.00%ZYXIZynex+5.94%-17.37%-7.36%-70.40%-78.27%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationINOInovio Pharmaceuticals3.6846 of 5 stars3.30.00.04.33.80.01.3MLSSMilestone Scientific2.9095 of 5 stars3.55.00.00.01.92.50.0PTHLPheton Holdings Ltd Class A Ordinary SharesN/AN/AN/AN/AN/AN/AN/AN/AZYXIZynex2.6817 of 5 stars3.20.00.00.01.61.73.1Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceINOInovio Pharmaceuticals 2.50Moderate Buy$9.75350.35% UpsideMLSSMilestone Scientific 3.00Buy$1.2537.21% UpsidePTHLPheton Holdings Ltd Class A Ordinary Shares 0.00N/AN/AN/AZYXIZynex 2.33Hold$6.00173.97% UpsideCurrent Analyst Ratings BreakdownLatest PTHL, MLSS, ZYXI, and INO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/14/2025INOInovio PharmaceuticalsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSector Perform ➝ Sector Perform$5.00 ➝ $5.005/14/2025INOInovio PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$15.00 ➝ $13.004/30/2025ZYXIZynexRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSector Perform ➝ Sector Perform$5.00 ➝ $4.004/30/2025ZYXIZynexHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$15.00 ➝ $8.004/15/2025ZYXIZynexRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSector Perform ➝ Sector Perform3/19/2025INOInovio PharmaceuticalsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSector Perform ➝ Sector Perform$6.00 ➝ $5.003/19/2025INOInovio PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$3.00 ➝ $3.003/12/2025ZYXIZynexHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$17.00 ➝ $15.003/12/2025ZYXIZynexRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Sector Perform$11.00 ➝ $5.503/12/2025ZYXIZynexLADENBURG THALM/SH SHSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral(Data available from 6/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookINOInovio Pharmaceuticals$283.10K280.46N/AN/A$5.16 per share0.42MLSSMilestone Scientific$8.61M8.30N/AN/A$0.11 per share8.28PTHLPheton Holdings Ltd Class A Ordinary Shares$448.20K89.95N/AN/AN/A∞ZYXIZynex$172.40M0.38$0.12 per share18.01$1.36 per share1.61Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateINOInovio Pharmaceuticals-$135.12M-$3.19N/AN/AN/AN/A-118.17%-83.47%8/14/2025 (Estimated)MLSSMilestone Scientific-$6.93M-$0.07N/A∞N/A-52.01%-60.26%-40.23%N/APTHLPheton Holdings Ltd Class A Ordinary SharesN/AN/A0.00∞N/AN/AN/AN/AN/AZYXIZynex$9.73M-$0.2414.604.66N/A2.49%13.05%3.78%7/23/2025 (Estimated)Latest PTHL, MLSS, ZYXI, and INO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025INOInovio Pharmaceuticals-$0.74-$0.51+$0.23-$0.51$0.01 million$0.07 million4/28/2025Q1 2025ZYXIZynex-$0.24-$0.33-$0.09-$0.33$30.83 million$26.58 million3/18/2025Q4 2024INOInovio Pharmaceuticals-$0.87-$0.69+$0.18-$0.60$0.03 million$0.12 million3/11/2025Q4 2024ZYXIZynex$0.09-$0.02-$0.11-$0.02$53.65 million$45.98 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthINOInovio PharmaceuticalsN/AN/AN/AN/AN/AMLSSMilestone ScientificN/AN/AN/AN/AN/APTHLPheton Holdings Ltd Class A Ordinary SharesN/AN/AN/AN/AN/AZYXIZynexN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioINOInovio PharmaceuticalsN/A3.883.88MLSSMilestone ScientificN/A2.851.86PTHLPheton Holdings Ltd Class A Ordinary SharesN/AN/AN/AZYXIZynex1.663.943.15Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipINOInovio Pharmaceuticals26.79%MLSSMilestone Scientific5.79%PTHLPheton Holdings Ltd Class A Ordinary SharesN/AZYXIZynex29.68%Insider OwnershipCompanyInsider OwnershipINOInovio Pharmaceuticals2.30%MLSSMilestone Scientific24.75%PTHLPheton Holdings Ltd Class A Ordinary SharesN/AZYXIZynex49.28%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableINOInovio Pharmaceuticals32036.67 million25.45 millionOptionableMLSSMilestone Scientific3078.48 million58.61 millionOptionablePTHLPheton Holdings Ltd Class A Ordinary Shares116.58 millionN/AN/AZYXIZynex77030.24 million15.25 millionOptionablePTHL, MLSS, ZYXI, and INO HeadlinesRecent News About These CompaniesZynex (NASDAQ:ZYXI) Stock Price Down 3.9% - What's Next?May 30, 2025 | marketbeat.comHere’s Why Zynex (ZYXI) Fell in Q1May 23, 2025 | msn.comZYXI DEADLINE ALERT: Zynex (ZYXI) Investors Alerted to Today’s Lead Plaintiff Deadline in Securities Class Action – Hagens BermanMay 21, 2025 | morningstar.comFINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of ZynexMay 21, 2025 | tmcnet.comZynex, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses; May 19, 2025 ...May 19, 2025 | gurufocus.comLost Money on Zynex, Inc. (ZYXI)? Contact Levi & Korsinsky Before May 19, 2025 to Join Class ActionMay 19, 2025 | accessnewswire.comZynex, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses; May 19, 2025 Deadline to file Lead Plaintiff MotionMay 19, 2025 | globenewswire.comZYXI Deadline: ZYXI Investors with Losses in Excess of $100K Have Opportunity to Lead Zynex, Inc. Securities Fraud LawsuitMay 19, 2025 | prnewswire.comZYXI Investors Have Opportunity to Lead Zynex, Inc. ...May 19, 2025 | gurufocus.comZYXI DEADLINE: ROSEN, LEADING TRIAL ATTORNEYS, Encourages Zynex, Inc. ...May 19, 2025 | gurufocus.comZYXI INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Zynex, Inc. ...May 19, 2025 | gurufocus.comZYXI LAWSUIT ALERT: Levi & Korsinsky Notifies Zynex, Inc. Investors - Lead Plaintiff Deadline May 19, 2025May 19, 2025 | accessnewswire.comZYXI Investors Have Opportunity to Lead Zynex, Inc. Securities Fraud Lawsuit with the Schall Law FirmMay 19, 2025 | businesswire.comZYXI INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Zynex, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitMay 19, 2025 | globenewswire.comZYXI DEADLINE: ROSEN, LEADING TRIAL ATTORNEYS, Encourages Zynex, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important May 19 Deadline in Securities Class Action – ZYXIMay 19, 2025 | globenewswire.comInvestors who lost money on Zynex, Inc.(ZYXI) should contact The Gross Law Firm about pending ...May 19, 2025 | gurufocus.comMay 19, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against ZYXIMay 19, 2025 | globenewswire.comInvestors who lost money on Zynex, Inc.(ZYXI) should contact The Gross Law Firm about pending Class Action - ZYXIMay 19, 2025 | prnewswire.comSecurities Lawsuit Alert: Zynex, Inc. (ZYXI) - Contact Levi & Korsinsky Before May 19, 2025May 19, 2025 | accessnewswire.comMay 19, 2025 Deadline: Join Class Action Lawsuit Against Zynex, Inc. (ZYXI) - Contact Levi & KorsinskyMay 19, 2025 | accessnewswire.comINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Zynex, Inc. of Class Action Lawsuit and Upcoming Deadlines - ZYXIMay 19, 2025 | accessnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePTHL, MLSS, ZYXI, and INO Company DescriptionsInovio Pharmaceuticals NASDAQ:INO$2.16 +0.05 (+2.12%) As of 12:15 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia; INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial; INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.Milestone Scientific NYSE:MLSS$0.91 -0.01 (-0.98%) As of 12:13 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Milestone Scientific Inc., a biomedical technology research and development company, patents, designs, develops, and commercializes diagnostic and therapeutic injection technologies, and devices for medical, dental, and cosmetic use in the United States, China, and internationally. The company operates through Dental and Medical segments. Its products include CompuDent and STA Single Tooth Anesthesia System that are used for all dental procedures that require local anesthetic. In addition, the company offers CompuFlo, a computer-controlled drug delivery system for the painless delivery of drugs, anesthetics, and other medicaments, as well as for the aspiration of bodily fluids or previously injected substances, and disposable injection handpiece for the tactile control during the injection. Further, it provides CompuFlo Epidural, a computer-controlled anesthesia system for use in various medical applications. Additionally, the company offers company offers CompuMed for use in various medical procedures performed in plastic, hair restoration, and colorectal surgery, as well as podiatry, dermatology, orthopedics, and various other disciplines. Milestone Scientific Inc. was incorporated in 1989 and is headquartered in Roseland, New Jersey.Pheton Holdings Ltd Class A Ordinary Shares NASDAQ:PTHL$6.12 +0.11 (+1.74%) As of 12:11 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Pheton Holdings Ltd. operates as a holding company with interests in providing healthcare solutions. The firm through its subsidiaries engages in the development and commercialization of brachytherapy TPS specifically used for radioactive particle implantation, a type of radiotherapy used in treating cancer patients by placing radioactive sources inside the patient that kill cancer cells and shrink tumors. The company was founded in 1998 and is headquartered in Beijing, China.Zynex NASDAQ:ZYXI$2.19 +0.05 (+2.34%) As of 12:12 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Zynex, Inc., together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device. It also supplies private labeled products, including electrodes for the delivery of electrical current to the body, and batteries for use in electrotherapy products. In addition, the company distributes Comfortrac/Saunders for cervical traction, JetStream for hot/cold therapy, LSO Back Braces for lumbar support, and braces for rehabilitation support. Further, it offers Zynex Fluid Monitoring System (CM-1500); Zynex Wireless Fluid Monitoring System (CM-1600), a noninvasive monitoring device designed to measure relative changes in fluid volume in adult patients; NiCO CO-Oximeter, a laser-based noninvasive co-oximeter; and HemeOx tHb Oximeter, a laser-based total hemoglobin pulse oximeter. The company provides its products for use in pain management and control; stroke and spinal cord injury rehabilitation; hemodynamic monitoring and intravascular volume monitoring; and pulse oximetry monitoring. It sells its products through direct sales force primarily in the United States. Zynex, Inc. was founded in 1996 and is headquartered in Englewood, Colorado. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas TSMC Joins NVIDIA in UAE Push, Fueling Growth Outlook Constellation Energy and Meta Strike Nuclear Deal, Shares Whipsaw Archer's Midnight Air Taxi Soars, But Stock Doesn’t Budge Microsoft Stock Near Peak, Pullback Seen as Opportunity 3 Reasons Amazon Could Be the Best Tech Performer in June 3 Tech Stocks Insiders Are Buying: Speculative Plays for June Tesla’s Lofty 200 P/E Could Mean More Upside Ollie’s Q1 Earnings: The Good, the Bad, and What’s Next Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.